Pulmotect, Inc., a clinical-stage biotechnology company and non-traditional Medical CBRN Defense Consortium (MCDC) member, is joining the fight against COVID-19.
The enormity of the coronavirus threat called for a rapid response, and the MCDC OTA was a key factor in supporting an accelerated solution to help expand COVID-19 testing.
The Medical CBRN Defense Consortium (MCDC) used the power of collaboration to drive innovation in response to the COVID-19 outbreak.
Through the new contract, awarded through the Medical CBRN Defense Consortium, Leidos plans to use a new clinical trial prototype, which uses an electronic data capture system to collect, evaluate and assess symptom severity.
Pulmotect, Inc., a clinical-stage biotechnology company, has received funding from the Department of Defense (DOD) to complete two ongoing COVID-19 Phase-2 clinical trials of its innate immune-stimulating drug PUL-042.
Medical CBRN Defense Consortium (MCDC) has released a Request for Information (RFI) seeking solutions to combat the novel Coronavirus (2019-nCoV) pandemic.